|
1
|
Chang J, Wu H, Wu J, Liu M, Zhang W, Hu Y,
Zhang X, Xu J, Li L, Yu P and Zhu J: Constructing a novel
mitochondrial-related gene signature for evaluating the tumor
immune microenvironment and predicting survival in stomach
adenocarcinoma. J Transl Med. 21:1912023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jin W, Ou K, Li Y, Liu W and Zhao M:
Metabolism-related long noncoding RNA in the stomach cancer
associated with 11 AMMLs predictive nomograms for OS in STAD. Front
Genet. 14:11271322023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Liu D, Wang Q and Xie Y:
Identification of basement membrane-related signatures in gastric
cancer. Diagnostics (Basel). 13:18442023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu B, Fu L, Guo X, Hu H, Li Y, Shi Y,
Zhang Y, Han S, Lv C and Tian Y: Multiomics profiling and digital
image analysis reveal the potential prognostic and
immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Front Immunol. 14:9848162023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao W, Lin J, Cheng S, Li H, Shu Y and Xu
C: Comprehensive analysis of COMMD10 as a novel prognostic
biomarker for gastric cancer. PeerJ. 11:e146452023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao Z, Mak TK, Shi Y, Li K, Huo M and
Zhang C: Integrative analysis of cancer-associated fibroblast
signature in gastric cancer. Heliyon. 9:e192172023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
8
|
Ajani JA, Lee J, Sano T, Janjigian YY, Fan
D and Song S: Gastric adenocarcinoma. Nat Rev Dis Primers.
3:170362017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahari D: Second-line chemotherapy for
patients with advanced gastric cancer. Gastric Cancer. 20:395–406.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnston FM and Beckman M: Updates on
management of gastric cancer. Curr Oncol Rep. 21:672019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hirschhorn T and Stockwell BR: The
development of the concept of ferroptosis. Free Radic Biol Med.
133:130–143. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao W, Wang X, Zhou Y, Wang X and Yu Y:
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor
immunotherapy. Signal Transduct Target Ther. 7:1962022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang D, Minikes AM and Jiang X:
Ferroptosis at the intersection of lipid metabolism and cellular
signaling. Mol Cell. 82:2215–2227. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Kang R and Tang D: Signaling
pathways and defense mechanisms of ferroptosis. FEBS J.
289:7038–7050. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu P, Wang W, Li Z, Li Y, Yu X, Tu J and
Zhang Z: Ferroptosis: A new regulatory mechanism in osteoporosis.
Oxid Med Cell Longev. 2022:26344312022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y, Wang Y, Guo L, Gao W, Tang TL and
Yan M: Interaction between macrophages and ferroptosis. Cell Death
Dis. 13:3552022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Zhou X, Xie F and Zhang L, Yan H,
Huang J, Zhang C, Zhou F, Chen J and Zhang L: Ferroptosis in cancer
and cancer immunotherapy. Cancer Commun (Lond). 42:88–116. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gong C, Ji Q, Wu M, Tu Z, Lei K, Luo M,
Liu J, Lin L, Li K, Li J, et al: Ferroptosis in tumor immunity and
therapy. J Cell Mol Med. 26:5565–5579. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Liu J, Xu Y, Wu R, Chen X, Song X,
Zeh H, Kang R, Klionsky DJ, Wang X and Tang D: Tumor heterogeneity
in autophagy-dependent ferroptosis. Autophagy. 17:3361–3374. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao P, Wang W, Wang W, Kryczek I, Li X,
Bian Y, Sell A, Wei S, Grove S, Johnson JK, et al: CD8(+) T cells
and fatty acids orchestrate tumor ferroptosis and immunity via
ACSL4. Cancer Cell. 40:365–378.e6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo T, Wang Y and Wang J: Ferroptosis
assassinates tumor. J Nanobiotechnology. 20:4672022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu D, Wang C, Yu L and Yu R: Induction of
ferroptosis by ATF3 elevation alleviates cisplatin resistance in
gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell Mol
Biol Lett. 26:262021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gu R, Xia Y, Li P, Zou D, Lu K, Ren L,
Zhang H and Sun Z: Ferroptosis and its Role in Gastric Cancer.
Front Cell Dev Biol. 10:8603442022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang G, Xiang Z, Wu H, He Q, Dou R, Lin
Z, Yang C, Huang S, Song J, Di Z, et al: The lncRNA
BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer
peritoneal metastasis by regulating VDAC3 ubiquitination. Int J
Biol Sci. 18:1415–1433. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li D, Wang Y, Dong C, Chen T, Dong A, Ren
J, Li W, Shu G, Yang J, Shen W, et al: CST1 inhibits ferroptosis
and promotes gastric cancer metastasis by regulating GPX4 protein
stability via OTUB1. Oncogene. 42:83–98. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin Z, Song J, Gao Y, Huang S, Dou R,
Zhong P, Huang G, Han L, Zheng J, Zhang X, et al: Hypoxia-induced
HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the
cytoplasmic translocation of ELAVL1 in peritoneal dissemination
from gastric cancer. Redox Biol. 52:1023122022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Song Z, Liu Y, Ma X, Wang W, Ke Y,
Xu Y, Yu D and Liu H: Identification of ferroptosis as a novel
mechanism for antitumor activity of natural product derivative a2
in gastric cancer. Acta Pharm Sin B. 11:1513–1525. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma M, Kong P, Huang Y, Wang J, Liu X, Hu
Y, Chen X, Du C and Yang H: Activation of MAT2A-ACSL3 pathway
protects cells from ferroptosis in gastric cancer. Free Radic Biol
Med. 181:288–299. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ouyang S, Li H, Lou L, Huang Q, Zhang Z,
Mo J, Li M, Lu J, Zhu K, Chu Y, et al: Inhibition of
STAT3-ferroptosis negative regulatory axis suppresses tumor growth
and alleviates chemoresistance in gastric cancer. Redox Biol.
52:1023172022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song S, Wen F, Gu S, Gu P, Huang W, Ruan
S, Chen X, Zhou J, Li Y, Liu J and Shu P: Network pharmacology
study and experimental validation of Yiqi Huayu decoction inducing
ferroptosis in gastric cancer. Front Oncol. 12:8200592022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Zheng L, Shang W, Yang Z, Li T,
Liu F, Shao W, Lv L, Chai L, Qu L, et al: Wnt/beta-catenin
signaling confers ferroptosis resistance by targeting GPX4 in
gastric cancer. Cell Death Differ. 29:2190–2202. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu C, Liu Z and Xiao J: Ferroptosis: A
double-edged sword in gastrointestinal disease. Int J Mol Sci.
22:124032021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu X and Li Y, Wu Y, Wang M, Lu Y, Fang Z,
Wang H and Li Y: Increased ATF2 expression predicts poor prognosis
and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox
Biol. 59:1025642023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang H, Hu Y, Weng M, Liu X, Wan P, Hu Y,
Ma M, Zhang Y, Xia H and Lv K: Hypoxia inducible lncRNA-CBSLR
modulates ferroptosis through m6A-YTHDF2-dependent modulation of
CBS in gastric cancer. J Adv Res. 37:91–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Z, Zou S, Zhang Y, Zhang J, Zhang P,
Xiao L, Xie Y, Meng M, Feng J, Kang L, et al: ACTL6A protects
gastric cancer cells against ferroptosis through induction of
glutathione synthesis. Nat Commun. 14:41932023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Wang M, He Y, Deng T, Liu R, Wang
W, Zhu K, Bai M, Ning T, Yang H, et al: Chemotoxicity-induced
exosomal lncFERO regulates ferroptosis and stemness in gastric
cancer stem cells. Cell Death Dis. 12:11162021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JY, Nam M, Son HY, Hyun K, Jang SY,
Kim JW, Kim MW, Jung Y, Jang E, Yoon SJ, et al: Polyunsaturated
fatty acid biosynthesis pathway determines ferroptosis sensitivity
in gastric cancer. Proc Natl Acad Sci USA. 117:32433–32442. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiao C, Dong T, Yang L, Jin L, Lin W,
Zhang F, Han Y and Huang Z: Identification of novel immune
ferropotosis-related genes associated with clinical and prognostic
features in gastric cancer. Front Oncol. 12:9043042022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng H, Lin Y, Gan F, Li B, Mou Z, Qin X,
He X and Meng Y: Prognostic model and immune infiltration of
ferroptosis subcluster-related modular genes in gastric cancer. J
Oncol. 2022:58135222022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng X, Dai E, Wu J, Flores NM, Chu Y,
Wang R, Dang M, Xu Z, Han G, Liu Y, et al: Atlas of metastatic
gastric cancer links ferroptosis to disease progression and
immunotherapy response. Gastroenterology. 167:1345–1357. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yue Z, Yuan Y, Zhou Q, Sheng J and Xin L:
Ferroptosis and its current progress in gastric cancer. Front Cell
Dev Biol. 12:12893352024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu M, Li H, Zhang H, Zhou H, Jiao T, Feng
M, Na F, Sun M, Zhao M, Xue L and Xu L: RBMS1 promotes gastric
cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling. Cell
Death Dis. 13:2872022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lodhi MS, Khan MT, Bukhari SMH, Sabir SH,
Samra ZQ, Butt H and Akram MS: Probing transferrin receptor
overexpression in gastric cancer mice models. ACS Omega.
6:29893–29904. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
You X, Ma M, Hou G, Hu Y and Shi X: Gene
expression and prognosis of NOX family members in gastric cancer.
Onco Targets Ther. 11:3065–3074. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Zhan J, Zhou J, Liu L, He Y, Le
Y, Liu W, Zhou L, Liu Y and Xiang X: Identification of HCAR1 as a
ferroptosis-related biomarker of gastric cancer based on a novel
ferroptosis-related prognostic model and in vitro experiments.
Carcinogenesis. 7:bgaf0302025. View Article : Google Scholar
|
|
48
|
Pourjamal N, Shirkoohi R, Rohani E and
Hashemi M: The expression analysis of MEST1 and GJA1 genes in
gastric cancer in association with clinicopathological
characteristics. Int J Hematol Oncol Stem Cell Res. 18:83–91.
2024.PubMed/NCBI
|
|
49
|
Wang Z, Chen C, Ai J, Shu J, Ding Y, Wang
W, Gao Y, Jia Y and Qin Y: Identifying mitophagy-related genes as
prognostic biomarkers and therapeutic targets of gastric carcinoma
by integrated analysis of single-cell and bulk-RNA sequencing data.
Comput Biol Med. 163:1072272023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC
and Jiang N: MiR-501-5p regulates CYLD expression and promotes cell
proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol.
45:738–744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gu Y, Wu S, Fan J, Meng Z, Gao G, Liu T,
Wang Q, Xia H, Wang X and Wu K: CYLD regulates cell ferroptosis
through Hippo/YAP signaling in prostate cancer progression. Cell
Death Dis. 15:792024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang M, Cheng S, Li Z, Chen J, Wang C, Li
J and Zheng H: Preconditioning exercise inhibits neuron ferroptosis
and ameliorates brain ischemia damage by skeletal muscle-derived
exosomes via regulating miR-484/ACSL4 axis. Antioxid Redox Signal.
41:769–792. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang J, Tian T, Li X, Yan Y, Zhao D, Ji
S, Ni J, Zhang J, Liu K, Qing H and Quan Z: p53 inhibits OTUD5
transcription to promote GPX4 degradation and induce ferroptosis in
gastric cancer. Clin Transl Med. 15:e702712025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lu D, Yuan L, Wang Z, Xu D, Meng F, Jia S,
Li Y, Li W and Nan Y: Dioscin induces ferroptosis to suppress the
metastasis of gastric cancer through the SLC7A11/GPX4 axis. Free
Radic Res. 59:426–441. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang H, Li C, Meng S and Kuang YT: The
LINC01094/miR-545-3p/SLC7A11 signaling axis promotes the
development of gastric cancer by regulating cell growth and
ferroptosis. Biochem Genet. https://doi.org/10.1007/s10528-024-10959-3
|
|
56
|
Xu Y, Hao J, Chen Q, Qin Y, Qin H, Ren S,
Sun C, Zhu Y, Shao B, Zhang J and Wang H: Inhibition of the
RBMS1/PRNP axis improves ferroptosis resistance-mediated
oxaliplatin chemoresistance in colorectal cancer. Mol Carcinog.
63:224–237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yu R, Li Z, Zhang C, Song H, Deng M, Sun
L, Xu L, Che X, Hu X, Qu X, et al: Elevated limb-bud and heart
development (LBH) expression indicates poor prognosis and promotes
gastric cancer cell proliferation and invasion by upregulating
Integrin/FAK/Akt pathway. PeerJ. 7:e68852019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Berthelet E, Pickles T, Lee KW, Liu M and
Truong PT; Prostate Cancer Outcomes Initiative, : Long-term
androgen deprivation therapy improves survival in prostate cancer
patients presenting with prostate-specific antigen levels >20
ng/ml. Int J Radiat Oncol Biol Phys. 63:781–787. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huang R, Lu TL and Zhou R: Identification
and immune landscape analysis of fatty acid metabolism genes
related subtypes of gastric cancer. Sci Rep. 13:204432023.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yuan Q, Deng D, Pan C, Ren J, Wei T, Wu Z,
Zhang B, Li S, Yin P and Shang D: Integration of transcriptomics,
proteomics, and metabolomics data to reveal HER2-associated
metabolic heterogeneity in gastric cancer with response to
immunotherapy and neoadjuvant chemotherapy. Front Immunol.
13:9511372022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang X, Zhang W, Guo Y, Zhang Y, Bai X and
Xie Y: Identification of critical prognosis signature associated
with lymph node metastasis of stomach adenocarcinomas. World J Surg
Oncol. 21:612023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Feng A, He L, Chen T and Xu M: A novel
cuproptosis-related lncRNA nomogram to improve the prognosis
prediction of gastric cancer. Front Oncol. 12:9579662022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chen J, Wang Y, Zhang W, Zhao D, Zhang L,
Zhang J, Fan J and Zhan Q: NOX5 mediates the crosstalk between
tumor cells and cancer-associated fibroblasts by regulating
cytokine network. Clin Transl Med. 11:e4722021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xiao R, Wang S, Guo J, Liu S, Ding A, Wang
G, Li W, Zhang Y, Bian X, Zhao S and Qiu W: Ferroptosis-related
gene NOX4, CHAC1 and HIF1A are valid biomarkers for stomach
adenocarcinoma. J Cell Mol Med. 26:1183–1193. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guo J, Xing W, Liu W, Liu J, Zhang J and
Pang Z: Prognostic value and risk model construction of hypoxic
stress-related features in predicting gastric cancer. Am J Transl
Res. 14:8599–8610. 2022.PubMed/NCBI
|
|
66
|
Chan JCY and Gorski SM: Unlocking the gate
to GABARAPL2. Biol Futur. 73:157–169. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Polletta L, Vernucci E, Carnevale I,
Arcangeli T, Rotili D, Palmerio S, Steegborn C, Nowak T,
Schutkowski M, Pellegrini L, et al: SIRT5 regulation of
ammonia-induced autophagy and mitophagy. Autophagy. 11:253–270.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Scicluna K, Dewson G, Czabotar PE and
Birkinshaw RW: A new crystal form of GABARAPL2. Acta Crystallogr F
Struct Biol Commun. 77:140–147. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang Z, Gu H, Li Q, Zheng J, Cao S, Weng
C and Jia H: GABARAPL2 is critical for growth restriction of
Toxoplasma gondii in HeLa cells treated with gamma
interferon. Infect Immun. 88:e00054–e00020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang M, Jing J, Li H, Liu J, Yuan Y and
Sun L: The expression characteristics and prognostic roles of
autophagy-related genes in gastric cancer. PeerJ. 9:e108142021.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fan D, Ren B, Yang X, Liu J and Zhang Z:
Upregulation of miR-501-5p activates the wnt/β-catenin signaling
pathway and enhances stem cell-like phenotype in gastric cancer. J
Exp Clin Cancer Res. 35:1772016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ma X, Feng J, Lu M, Tang W, Han J, Luo X,
Zhao Q and Yang L: microRNA-501-5p promotes cell proliferation and
migration in gastric cancer by downregulating LPAR1. J Cell
Biochem. 121:1911–1922. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zare A, Ahadi A, Larki P, Omrani MD, Zali
MR, Alamdari NM and Ghaedi H: The clinical significance of miR-335,
miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol
Biol Rep. 45:1587–1595. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu J and Li SM: MiR-484 suppressed
proliferation, migration, invasion and induced apoptosis of gastric
cancer by targeting CCL-18. Int J Exp Pathol. 101:203–214. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li Y, Liu Y, Yao J, LI R and Fan X:
Downregulation of miR-484 is associated with poor prognosis and
tumor progression of gastric cancer. Diagn Pathol. 15:252020.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang L and Gong W: NOX4 regulates gastric
cancer cell invasion and proliferation by increasing ferroptosis
sensitivity through regulating ROS. Int Immunopharmacol.
132:1120522024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang D, Yan H, Li H, Hao S, Zhuang Z, Liu
M, Sun Q, Yang Y, Zhou M, Li K and Hang C: TGFβ-activated kinase 1
(TAK1) inhibition by 5Z-7-Oxozeaenol attenuates early brain injury
after experimental subarachnoid Hemorrhage. J Biol Chem.
290:19900–19909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yang Y, Qiu Y, Tang M, Wu Z, Hu W and Chen
C: Expression and function of transforming growth
factor-β-activated protein kinase 1 in gastric cancer. Mol Med Rep.
16:3103–3110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ahn S, Brant R, Sharpe A, Dry JR, Hodgson
DR, Kilgour E, Kim K, Kim ST, Park SH, Kang WK, et al: Correlation
between MEK signature and Ras gene alteration in advanced gastric
cancer. Oncotarget. 8:107492–107499. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lee J, Kim ST, Kim K, Lee H, Kozarewa I,
Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, et al:
Tumor genomic profiling guides patients with metastatic gastric
cancer to targeted treatment: The VIKTORY umbrella trial. Cancer
Discov. 9:1388–1405. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liu Z and Xing M: Induction of
sodium/iodide symporter (NIS) expression and radioiodine uptake in
nonthyroid cancer cells. PLoS One. 7:e317292012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wu X, Zhou F, Cheng B, Tong G, Chen M, He
L, Li Z, Yu S, Wang S and Lin L: Immune activity score to assess
the prognosis, immunotherapy and chemotherapy response in gastric
cancer and experimental validation. PeerJ. 11:e163172023.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Liu J, Zhang B, Zhang Y, Zhao H, Chen X,
Zhong L and Shang D: Oxidative stress and autophagy-mediated immune
patterns and tumor microenvironment infiltration characterization
in gastric cancer. Aging (Albany NY). 15:12513–12536. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ajani JA, D'Amico TA, Bentrem DJ, Corvera
CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P,
et al: Gastric cancer, version 2.2025, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 23:169–191. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Dai C, Shen L, Jin W, Lv B, Liu P, Wang X,
Yin Y, Fu Y, Liang L, Ma Z, et al: Physapubescin B enhances the
sensitivity of gastric cancer cells to trametinib by inhibiting the
STAT3 signaling pathway. Toxicol Appl Pharmacol. 408:1152732020.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu H, Yao Y, Zhang J and Li J: MEK
inhibition overcomes everolimus resistance in gastric cancer.
Cancer Chemother Pharmacol. 85:1079–1087. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang Z, Chen Y, Li X, Zhang Y, Zhao X,
Zhou H, Lu X, Zhao L, Yuan Q, Shi Y, et al: Tegaserod maleate
suppresses the growth of gastric cancer in vivo and in vitro by
targeting MEK1/2. Cancers (Basel). 14:35922022. View Article : Google Scholar : PubMed/NCBI
|
